| abstract |
The present invention relates to novel biologically active molecules that bind to and inhibit thrombin. More particularly, these molecules are characterized by a fraction of anion associations of thrombin-binding exosite (ABEAM); a connecting portion at least 18 Å in length; and a fraction directed to the catalytic site of thrombin (CSDM). The invention also relates to compositions, combinations and methods which use these molecules for therapeutic, prophylactic and diagnostic purposes. |